Standard

Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. / Slagter, Astrid E.; Caspers, Irene A.; van Grieken, Nicole C. T. et al.
In: Cancers, Vol. 14, No. 12, 2963, 01.06.2022.

Research output: Contribution to journal › Article › Academic › peer-review

Harvard

Slagter, AE, Caspers, IA, van Grieken, NCT, Walraven, I, Lind, P, Kranenbarg, EM-K, Grootscholten, C, Nordsmark, M, van Sandick, JW, Sikorska, K, van de Velde, CJH, Jansen, EPM, Verheij, M, van Laarhoven, HWM & Cats, A 2022, 'Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer', Cancers, vol. 14, no. 12, 2963. https://doi.org/10.3390/cancers14122963

APA

Slagter, A. E., Caspers, I. A., van Grieken, N. C. T., Walraven, I., Lind, P., Kranenbarg, E. M-K., Grootscholten, C., Nordsmark, M., van Sandick, J. W., Sikorska, K., van de Velde, C. J. H., Jansen, E. P. M., Verheij, M., van Laarhoven, H. W. M., & Cats, A. (2022). Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. Cancers, 14(12), [2963]. https://doi.org/10.3390/cancers14122963

Vancouver

Slagter AE, Caspers IA, van Grieken NCT, Walraven I, Lind P, Kranenbarg EM-K et al. Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. Cancers. 2022 Jun 1;14(12):2963. doi: 10.3390/cancers14122963

Author

Slagter, Astrid E. ; Caspers, Irene A. ; van Grieken, Nicole C. T. et al. / Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial : Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. In: Cancers. 2022 ; Vol. 14, No. 12.

BibTeX

@article{7d31485778fd48a69f94474112330463,
title = "Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer",
abstract = "(1) Background: Perioperative chemotherapy is the current standard treatment for patients with resectable gastric cancer. Based on studies in patients with metastatic gastric cancer, oxaliplatin has replaced cisplatin in the curative setting as well. However, evidence to prefer oxaliplatin over cisplatin in the curative setting is limited. (2) Methods: We compared patientrelated and tumor-related outcomes for cisplatin versus oxaliplatin in patients with resectable gastric cancer treated with perioperative chemotherapy in the CRITICS trial. (3) Results: Preoperatively, 632 patients received cisplatin and 149 patients received oxaliplatin. Preoperative severe toxicity was encountered in 422 (67%) patients who received cisplatin versus 89 (60%) patients who received oxaliplatin (p = 0.105). Severe neuropathy was observed in 5 (1%) versus 6 (4%; p = 0.009) patients, respectively. Postoperative severe toxicity occurred in 109 (60%) versus 26 (51%) (p = 0.266) patients; severe neuropathy in 2 (1%) versus 2 (4%; p = 0.209) for patients who received cisplatin or oxaliplatin, respectively. Diarrhea impacted the quality of life more frequently in patients who received oxaliplatin compared to cisplatin. Complete or near-complete pathological response was achieved in 94 (21%) versus 16 (15%; p = 0.126) patients who received cisplatin or oxaliplatin, respectively. Overall survival was not significantly different in both groups (p = 0.300). (4) Conclusions: Both cisplatin and oxaliplatin are legitimate options as part of systemic treatment in patients with resectable gastric cancer.",
keywords = "chemotherapy, cisplatin, oxaliplatin, resectable gastric cancer",
author = "Slagter, {Astrid E.} and Caspers, {Irene A.} and {van Grieken}, {Nicole C. T.} and Iris Walraven and Pehr Lind and Kranenbarg, {Elma Meershoek-Klein} and Cecile Grootscholten and Marianne Nordsmark and {van Sandick}, {Johanna W.} and Karolina Sikorska and {van de Velde}, {Cornelis J. H.} and Jansen, {Edwin P. M.} and Marcel Verheij and {van Laarhoven}, {Hanneke W. M.} and Annemieke Cats",
note = "Funding Information: Funding: The CRITICS trial was funded by the Dutch Cancer Society, the Dutch Colorectal Cancer Group, and Hoffmann La Roche. No additional funding was used for the current analysis. The funding sources had no role in the design, collection, analysis, and interpretation of the data. Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2022",
month = jun,
day = "1",
doi = "10.3390/cancers14122963",
language = "English",
volume = "14",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

RIS

TY - JOUR

T1 - Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial

T2 - Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer

AU - Slagter, Astrid E.

AU - Caspers, Irene A.

AU - van Grieken, Nicole C. T.

AU - Walraven, Iris

AU - Lind, Pehr

AU - Kranenbarg, Elma Meershoek-Klein

AU - Grootscholten, Cecile

AU - Nordsmark, Marianne

AU - van Sandick, Johanna W.

AU - Sikorska, Karolina

AU - van de Velde, Cornelis J. H.

AU - Jansen, Edwin P. M.

AU - Verheij, Marcel

AU - van Laarhoven, Hanneke W. M.

AU - Cats, Annemieke

N1 - Funding Information: Funding: The CRITICS trial was funded by the Dutch Cancer Society, the Dutch Colorectal Cancer Group, and Hoffmann La Roche. No additional funding was used for the current analysis. The funding sources had no role in the design, collection, analysis, and interpretation of the data. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/6/1

Y1 - 2022/6/1

N2 - (1) Background: Perioperative chemotherapy is the current standard treatment for patients with resectable gastric cancer. Based on studies in patients with metastatic gastric cancer, oxaliplatin has replaced cisplatin in the curative setting as well. However, evidence to prefer oxaliplatin over cisplatin in the curative setting is limited. (2) Methods: We compared patientrelated and tumor-related outcomes for cisplatin versus oxaliplatin in patients with resectable gastric cancer treated with perioperative chemotherapy in the CRITICS trial. (3) Results: Preoperatively, 632 patients received cisplatin and 149 patients received oxaliplatin. Preoperative severe toxicity was encountered in 422 (67%) patients who received cisplatin versus 89 (60%) patients who received oxaliplatin (p = 0.105). Severe neuropathy was observed in 5 (1%) versus 6 (4%; p = 0.009) patients, respectively. Postoperative severe toxicity occurred in 109 (60%) versus 26 (51%) (p = 0.266) patients; severe neuropathy in 2 (1%) versus 2 (4%; p = 0.209) for patients who received cisplatin or oxaliplatin, respectively. Diarrhea impacted the quality of life more frequently in patients who received oxaliplatin compared to cisplatin. Complete or near-complete pathological response was achieved in 94 (21%) versus 16 (15%; p = 0.126) patients who received cisplatin or oxaliplatin, respectively. Overall survival was not significantly different in both groups (p = 0.300). (4) Conclusions: Both cisplatin and oxaliplatin are legitimate options as part of systemic treatment in patients with resectable gastric cancer.

AB - (1) Background: Perioperative chemotherapy is the current standard treatment for patients with resectable gastric cancer. Based on studies in patients with metastatic gastric cancer, oxaliplatin has replaced cisplatin in the curative setting as well. However, evidence to prefer oxaliplatin over cisplatin in the curative setting is limited. (2) Methods: We compared patientrelated and tumor-related outcomes for cisplatin versus oxaliplatin in patients with resectable gastric cancer treated with perioperative chemotherapy in the CRITICS trial. (3) Results: Preoperatively, 632 patients received cisplatin and 149 patients received oxaliplatin. Preoperative severe toxicity was encountered in 422 (67%) patients who received cisplatin versus 89 (60%) patients who received oxaliplatin (p = 0.105). Severe neuropathy was observed in 5 (1%) versus 6 (4%; p = 0.009) patients, respectively. Postoperative severe toxicity occurred in 109 (60%) versus 26 (51%) (p = 0.266) patients; severe neuropathy in 2 (1%) versus 2 (4%; p = 0.209) for patients who received cisplatin or oxaliplatin, respectively. Diarrhea impacted the quality of life more frequently in patients who received oxaliplatin compared to cisplatin. Complete or near-complete pathological response was achieved in 94 (21%) versus 16 (15%; p = 0.126) patients who received cisplatin or oxaliplatin, respectively. Overall survival was not significantly different in both groups (p = 0.300). (4) Conclusions: Both cisplatin and oxaliplatin are legitimate options as part of systemic treatment in patients with resectable gastric cancer.

KW - chemotherapy

KW - cisplatin

KW - oxaliplatin

KW - resectable gastric cancer

UR - http://www.scopus.com/inward/record.url?scp=85131889680&partnerID=8YFLogxK

U2 - 10.3390/cancers14122963

DO - 10.3390/cancers14122963

M3 - Article

C2 - 35740628

VL - 14

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 12

M1 - 2963

ER -

ID: 24878542